Page last updated: 2024-10-20
uracil and Anorexia
uracil has been researched along with Anorexia in 26 studies
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder
Anorexia: The lack or loss of APPETITE accompanied by an aversion to food and the inability to eat. It is the defining characteristic of the disorder ANOREXIA NERVOSA.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| "We investigated the efficacy and safety of oral Uracil/tegafur (UFT) with leucovorin and mitomycin C (MMC) as third-line treatment for patients with extensively pretreated metastatic colorectal cancer (mCRC)." | 9.16 | Uracil-tegafur/leucovorin and mitomycin C salvage therapy in patients with advanced colorectal cancer: a phase II study. ( Chamorey, E; Dahan, L; Evesque, L; Follana, P; Francois, E; Mari, V; Michel, C; Perrier, H; Seitz, JF; Smith, D, 2012) |
| "Sorafenib, a multi-kinase inhibitor with anti-angiogenic activity, was recently approved for the treatment of advanced hepatocellular carcinoma (HCC)." | 9.14 | Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. ( Chen, PJ; Cheng, AL; Ding, YH; Hsu, C; Hsu, CH; Lin, ZZ; Shao, YY; Shen, YC, 2010) |
| "We performed a controlled study to compare the response to cyclophosphamide (CPA), adriamycin (ADM), and fluorouracil (5-FU) (CAF therapy) with that to uracil-tegafur (UFT) plus tamoxifen (TAM) (UFT+TAM therapy), when given as postoperative adjuvant therapy to women with breast cancer." | 9.12 | [A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant set ( Inaji, H; Koyama, H; Mori, T; Nakao, K; Oka, T; Oshima, A; Ozawa, K; Saito, Y; Sakai, K; Senoo, T; Taguchi, T; Terasawa, T, 2006) |
| "This study aimed to clarify the tolerability of a trifluridine/tipiracil combination tablet (TAS-102) in patients with advanced or recurrent colorectal cancer over 75 years of age." | 7.91 | Evaluation of Tolerability of Trifluridine/Tipiracil Combination Tablet in Patients With Advanced/Recurrent Colorectal Cancer. ( Kimura, M; Teramachi, H; Usami, E; Yoshimura, T, 2019) |
| "The uracil/tegafur (UFT) plus oral Leucovorin (LV) regimen is one of the standard chemotherapy modalities for colorectal cancer, and has been reported to have fewer side effects." | 7.73 | [Efficacy of uracil/tegafur (UFT) plus oral Leucovorin (LV) therapy for colorectal cancer in elderly patients]. ( Hoki, M; Ito, T; Iwamoto, T; Iwase, K; Kanou, T; Mizuno, H; Mizushima, T; Nakamori, Y; Ozawa, H; Souma, Y, 2006) |
| "We investigated the efficacy and safety of oral Uracil/tegafur (UFT) with leucovorin and mitomycin C (MMC) as third-line treatment for patients with extensively pretreated metastatic colorectal cancer (mCRC)." | 5.16 | Uracil-tegafur/leucovorin and mitomycin C salvage therapy in patients with advanced colorectal cancer: a phase II study. ( Chamorey, E; Dahan, L; Evesque, L; Follana, P; Francois, E; Mari, V; Michel, C; Perrier, H; Seitz, JF; Smith, D, 2012) |
| "Sorafenib, a multi-kinase inhibitor with anti-angiogenic activity, was recently approved for the treatment of advanced hepatocellular carcinoma (HCC)." | 5.14 | Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. ( Chen, PJ; Cheng, AL; Ding, YH; Hsu, C; Hsu, CH; Lin, ZZ; Shao, YY; Shen, YC, 2010) |
| "Two phase III studies revealed an oral UFT/Leucovorin (LV) regimen, in which the drugs are taken for 28 consecutive days every 35 days, which proved to be equivalent to an infusional 5-fluorouracil/LV regimen for metastatic colorectal cancer (CRC)." | 5.12 | [Feasibility of weekday-on/weekend-off oral UFT/Leucovorin schedule as postoperative adjuvant chemotherapy for colorectal cancer]. ( Maeda, Y; Makuuchi, H; Murayama, C; Sadahiro, S; Suzuki, T, 2006) |
| "We performed a controlled study to compare the response to cyclophosphamide (CPA), adriamycin (ADM), and fluorouracil (5-FU) (CAF therapy) with that to uracil-tegafur (UFT) plus tamoxifen (TAM) (UFT+TAM therapy), when given as postoperative adjuvant therapy to women with breast cancer." | 5.12 | [A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant set ( Inaji, H; Koyama, H; Mori, T; Nakao, K; Oka, T; Oshima, A; Ozawa, K; Saito, Y; Sakai, K; Senoo, T; Taguchi, T; Terasawa, T, 2006) |
| "This study aimed to clarify the tolerability of a trifluridine/tipiracil combination tablet (TAS-102) in patients with advanced or recurrent colorectal cancer over 75 years of age." | 3.91 | Evaluation of Tolerability of Trifluridine/Tipiracil Combination Tablet in Patients With Advanced/Recurrent Colorectal Cancer. ( Kimura, M; Teramachi, H; Usami, E; Yoshimura, T, 2019) |
| "The uracil/tegafur (UFT) plus oral Leucovorin (LV) regimen is one of the standard chemotherapy modalities for colorectal cancer, and has been reported to have fewer side effects." | 3.73 | [Efficacy of uracil/tegafur (UFT) plus oral Leucovorin (LV) therapy for colorectal cancer in elderly patients]. ( Hoki, M; Ito, T; Iwamoto, T; Iwase, K; Kanou, T; Mizuno, H; Mizushima, T; Nakamori, Y; Ozawa, H; Souma, Y, 2006) |
| "A phase II evaluation of UFT, a mixture of tegafur and uracil, was performed in 13 patients with non-small cell lung cancer (eight patients with adenocarcinoma and five patients with squamous cell carcinoma)." | 3.67 | [A phase II study of UFT in non-small cell lung cancer]. ( Hojo, F; Inoue, I; Kimura, K; Nakamura, Y; Nakanishi, S; Noda, Y; Shimizu, E; Sone, S; Yagi, M; Yamasaki, K, 1986) |
| "The prognosis for locally advanced gastric cancer is poor despite advances in adjuvant chemotherapy." | 2.79 | Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial. ( Buyse, M; Fukushima, R; Hara, A; Imamura, H; Kobayashi, M; Kojima, H; Miyashita, Y; Morita, S; Nishikawa, K; Nozaki, I; Oba, K; Sakamoto, J; Takahashi, M; Takahashi, N; Takiguchi, N; Tanabe, K; Tatsumoto, N; Tsuburaya, A; Yoshida, K; Yoshino, S, 2014) |
| "Forty-eight patients with unresectable gastric cancer were enrolled for a randomized trial of FP (n = 24) vs FEP (n = 24) combination chemotherapy with respect to their effects on survival period." | 2.68 | [Combination chemotherapy with FP versus FEP in patients with advanced gastric cancer. Research group of gastric cancer chemotherapy]. ( Horiuchi, Y; Ina, K; Iwase, H; Kaneko, H; Kuroiwa, A; Kusugami, K; Morise, K; Oka, Y; Shinoda, M; Suga, S, 1995) |
| "We report a rare patient with a DPD deficiency." | 1.33 | [A case of recurrent gastric cancer with dihydropyrimidine dehydrogenase (DPD) deficiency]. ( Arai, K; Hashimoto, T; Hiruma, K; Iwasaki, Y; Matsumoto, H; Saze, Z; Takahashi, K; Yamaguchi, T; Yamashita, Y; Yasutome, M, 2006) |
| "There were PR cases in hepatoma and breast cancer also." | 1.27 | [Clinical results of treatment with the UFT fine granule preparation under cooperative study. Tokyo Cancer Chemotherapy Cooperative Study Group]. ( Futatsuki, K; Kamano, T; Komita, T; Watanabe, H, 1987) |
| " Total Ftorafur (FT) results using the same criteria from the UFT phase II study revealed, from a comparison of dosage and disease type, that UFT did not enhance FT side effects; rather, it markedly increases effectiveness." | 1.27 | [Report on nationwide pooled data and cohort investigation in UFT phase II study]. ( Kimura, K; Ota, K; Taguchi, T, 1987) |
Research
Studies (26)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (23.08) | 18.7374 |
| 1990's | 7 (26.92) | 18.2507 |
| 2000's | 7 (26.92) | 29.6817 |
| 2010's | 5 (19.23) | 24.3611 |
| 2020's | 1 (3.85) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Okamoto, K | 1 |
| Kaku, R | 1 |
| Oshio, Y | 1 |
| Hanaoka, J | 1 |
| Kimura, M | 2 |
| Usami, E | 1 |
| Teramachi, H | 1 |
| Yoshimura, T | 1 |
| Tsuburaya, A | 1 |
| Yoshida, K | 1 |
| Kobayashi, M | 1 |
| Yoshino, S | 1 |
| Takahashi, M | 1 |
| Takiguchi, N | 1 |
| Tanabe, K | 1 |
| Takahashi, N | 1 |
| Imamura, H | 1 |
| Tatsumoto, N | 1 |
| Hara, A | 1 |
| Nishikawa, K | 1 |
| Fukushima, R | 1 |
| Nozaki, I | 1 |
| Kojima, H | 1 |
| Miyashita, Y | 1 |
| Oba, K | 1 |
| Buyse, M | 1 |
| Morita, S | 1 |
| Sakamoto, J | 1 |
| Hsu, CH | 1 |
| Shen, YC | 1 |
| Lin, ZZ | 1 |
| Chen, PJ | 1 |
| Shao, YY | 1 |
| Ding, YH | 1 |
| Hsu, C | 1 |
| Cheng, AL | 1 |
| Tsunoda, A | 1 |
| Nakao, K | 2 |
| Watanabe, M | 1 |
| Francois, E | 1 |
| Smith, D | 1 |
| Dahan, L | 1 |
| Michel, C | 1 |
| Perrier, H | 1 |
| Mari, V | 1 |
| Seitz, JF | 1 |
| Follana, P | 1 |
| Evesque, L | 1 |
| Chamorey, E | 1 |
| Fujimori, S | 1 |
| Kurita, H | 1 |
| Azegami, T | 1 |
| Koike, T | 1 |
| Ohtsuka, A | 1 |
| Kobayashi, H | 1 |
| Tanaka, K | 2 |
| Kurashina, K | 1 |
| Sadahiro, S | 2 |
| Mitomi, T | 1 |
| Noto, T | 1 |
| Kumada, K | 1 |
| Hiki, Y | 1 |
| Yamakawa, T | 1 |
| Amano, T | 1 |
| Oki, S | 1 |
| Otani, Y | 1 |
| Oka, H | 1 |
| Takahashi, T | 2 |
| Takemiya, S | 1 |
| Nishiyama, K | 1 |
| Yamamura, T | 1 |
| Tsuchiya, S | 1 |
| Ogawa, N | 1 |
| Suzuki, T | 1 |
| Maeda, Y | 1 |
| Makuuchi, H | 1 |
| Murayama, C | 1 |
| Iwamoto, S | 1 |
| Yoshioka, K | 1 |
| Mizushima, T | 1 |
| Mizuno, H | 1 |
| Ito, T | 1 |
| Hoki, M | 1 |
| Souma, Y | 1 |
| Iwamoto, T | 1 |
| Ozawa, H | 1 |
| Kanou, T | 1 |
| Nakamori, Y | 1 |
| Iwase, K | 1 |
| Hashimoto, T | 1 |
| Arai, K | 1 |
| Iwasaki, Y | 1 |
| Saze, Z | 1 |
| Takahashi, K | 1 |
| Yamaguchi, T | 1 |
| Matsumoto, H | 1 |
| Yasutome, M | 1 |
| Hiruma, K | 1 |
| Yamashita, Y | 1 |
| Inaji, H | 1 |
| Sakai, K | 1 |
| Oka, T | 1 |
| Ozawa, K | 1 |
| Saito, Y | 1 |
| Senoo, T | 1 |
| Taguchi, T | 3 |
| Terasawa, T | 1 |
| Mori, T | 1 |
| Koyama, H | 1 |
| Oshima, A | 1 |
| Shinoda, M | 1 |
| Morise, K | 1 |
| Kusugami, K | 1 |
| Iwase, H | 1 |
| Ina, K | 1 |
| Kaneko, H | 1 |
| Horiuchi, Y | 1 |
| Kuroiwa, A | 1 |
| Suga, S | 1 |
| Oka, Y | 1 |
| Kodama, S | 1 |
| Nakamura, M | 1 |
| Honma, S | 1 |
| Maruhashi, T | 1 |
| Tokunaga, A | 1 |
| Takeuchi, Y | 1 |
| Sudou, N | 1 |
| Adachi, S | 1 |
| Kurihara, M | 2 |
| Horikoshi, N | 1 |
| Aiba, K | 1 |
| Kanamaru, R | 1 |
| Hasegawa, K | 1 |
| Takeda, S | 1 |
| Niitani, H | 1 |
| Furue, H | 1 |
| Ogawa, M | 1 |
| Abe, T | 1 |
| Mani, S | 1 |
| Kugler, JW | 1 |
| Sciortino, DF | 1 |
| Garcia, JC | 1 |
| Ansari, RH | 1 |
| Humerickhouse, R | 1 |
| Michelassi, F | 1 |
| Posner, MC | 1 |
| Shulman, KL | 1 |
| Schilsky, RL | 1 |
| List, M | 1 |
| Vokes, EE | 1 |
| Benner, S | 1 |
| Sakata, Y | 1 |
| Chiba, Y | 1 |
| Sato, T | 1 |
| Fukushi, G | 1 |
| Matsukawa, M | 1 |
| Wada, K | 1 |
| Aoyama, H | 1 |
| Sawada, Y | 1 |
| Fukushi, M | 1 |
| Kikuchi, K | 1 |
| Wakui, A | 1 |
| Shimizu, E | 1 |
| Kimura, K | 2 |
| Sone, S | 1 |
| Inoue, I | 1 |
| Nakamura, Y | 1 |
| Noda, Y | 1 |
| Hojo, F | 1 |
| Yagi, M | 1 |
| Nakanishi, S | 1 |
| Yamasaki, K | 1 |
| Futatsuki, K | 1 |
| Komita, T | 1 |
| Kamano, T | 1 |
| Watanabe, H | 1 |
| Ota, K | 1 |
| Niijima, T | 1 |
| Aso, Y | 1 |
| Akaza, H | 1 |
| Kameyama, S | 1 |
| Koiso, K | 1 |
| Kawabe, K | 1 |
| Kawamura, T | 1 |
| Isurugi, K | 1 |
| Yokoyama, M | 1 |
| Shoji, F | 1 |
| Naito, K | 1 |
| Hisazumi, H | 1 |
| Misaki, T | 1 |
| Shimada, K | 1 |
| Miyazaki, K | 1 |
| Kosaka, S | 1 |
| Miyagi, T | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective,Multicentral,Open-label,Randomized,Controlled,Phase III Clinical Trial to Compare S-1 for 6 Months to 1 Year as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric Cancer Staged II , IIIA or IIIB.[NCT02736552] | Phase 3 | 0 participants (Actual) | Interventional | 2016-03-31 | Withdrawn | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Trials
13 trials available for uracil and Anorexia
| Article | Year |
|---|---|
Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial.
Topics: Adenocarcinoma; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2014 |
Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Benzenesul | 2010 |
Uracil-tegafur/leucovorin and mitomycin C salvage therapy in patients with advanced colorectal cancer: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Agents; Antineoplastic Combined Chemotherap | 2012 |
[Multicenter comparative study of the recurrence-inhibitory effect of oral fluoropyrimidine drugs in patients with colorectal cancer following curative resection].
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Pr | 2005 |
[Feasibility of weekday-on/weekend-off oral UFT/Leucovorin schedule as postoperative adjuvant chemotherapy for colorectal cancer].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anemia; Anorexia; Antineoplastic Combined Chem | 2006 |
[A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant set
Topics: Anorexia; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Ne | 2006 |
[Combination chemotherapy with FP versus FEP in patients with advanced gastric cancer. Research group of gastric cancer chemotherapy].
Topics: Adenocarcinoma; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Admi | 1995 |
[Clinical results of UFT against ovarian carcinoma].
Topics: Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Female; | 1994 |
UFT plus cisplatin for advanced gastric cancer.
Topics: Adolescent; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Diarrh | 1997 |
[Phase I study of orally administered UFT plus l-leucovorin].
Topics: Administration, Oral; Adolescent; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protoc | 1998 |
Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced pancreatic carcinoma: a University of Chicago phase II consortium study.
Topics: Adenocarcinoma; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Leuc | 1998 |
[Comparative study of UFT plus mitomycin C and UFT plus doxorubicin in adenocarcinoma. Hirosaki Cooperative Group of Cancer Chemotherapy].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Proto | 1992 |
[Cooperative research of UFT E phase II study. Cooperative Study Group of UFT E in Tohoku Area].
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; | 1990 |
Other Studies
13 other studies available for uracil and Anorexia
| Article | Year |
|---|---|
Impact of thoracic esophageal displacement after lobectomy on the continuity of oral adjuvant chemotherapy.
Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chem | 2022 |
Evaluation of Tolerability of Trifluridine/Tipiracil Combination Tablet in Patients With Advanced/Recurrent Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Co | 2019 |
[Compliance of oral UFT plus leucovorin adjuvant chemotherapy in patients who underwent curative resection for colorectal cancer].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy | 2010 |
[Neoadjuvant chemotherapy with nedaplatin and UFT for oral squamous cell carcinomas].
Topics: Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamo | 2003 |
[24 hour infusion of CPT-11/oral UFT/LV].
Topics: Administration, Oral; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2006 |
[Efficacy of uracil/tegafur (UFT) plus oral Leucovorin (LV) therapy for colorectal cancer in elderly patients].
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2006 |
[A case of recurrent gastric cancer with dihydropyrimidine dehydrogenase (DPD) deficiency].
Topics: Adult; Anorexia; Antimetabolites, Antineoplastic; Bone Neoplasms; Cerebral Hemorrhage; Dihydropyrimi | 2006 |
[UFT].
Topics: Anorexia; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Combina | 1984 |
[A phase II study of UFT in non-small cell lung cancer].
Topics: Adenocarcinoma; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small | 1986 |
[Clinical results of treatment with the UFT fine granule preparation under cooperative study. Tokyo Cancer Chemotherapy Cooperative Study Group].
Topics: Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Breast | 1987 |
[Report on nationwide pooled data and cohort investigation in UFT phase II study].
Topics: Anorexia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Sche | 1987 |
[Collaborative study of UFT in far-advanced renal cell carcinoma. Urological Cooperative UFT Study Group].
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Drug A | 1988 |
[Clinical effect of UFT on prostatic cancer].
Topics: Adenocarcinoma; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Hum | 1985 |